Improving Alzheimer’s Disease Management
Updates on Patient Diagnosis and Treatment
2023 Alzheimer’s disease facts and figures.
Alzheimer’s Association.
The Alzheimer's disease clinical spectrum: diagnosis and management.
Atri A. Med Clin North Am. 2019;103(2):263-293.
Apoe4 is a risk factor and potential therapeutic target for Alzheimer's disease.
Ayyubova G. CNS Neurol Disord Drug Targets. 2023. [Epub ahead of print]
Neuropathological stageing of Alzheimer-related changes.
Braak H, Braak E. Acta Neuropathol. 1991;82(4):239-259.
Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: the role of CSF biomarkers during the evolution of diagnostic criteria.
Dulewicz M, Kulczyńska-Przybik A, Mroczko P, et al. Int J Mol Sci. 2022;23(15):8598.
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised.
Frisoni GB, Altomare D, Thal DR, et al. Nat Rev Neurosci. 2022;23(1):53-66.
A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers.
Jack CR Jr, Bennett DA, Blennow K, et al. Neurology. 2016;87(5):539-547.
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Jack CR, Jr., Bennett DA, Blennow K, et al. Alzheimers Dement. 2018;14(4):535-562.
Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: a systematic review.
Jeremic D, Jiménez-Díaz L, Navarro-López JD. Ageing Res Rev. 2021;72:101496.
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng F, Edison P. Nat Rev Neurol. 2021;17(3):157-172.
Development of Alzheimer's disease biomarkers: from CSF- to blood-based biomarkers.
Mankhong S, Kim S, Lee S, et al. Biomedicines. 2022;10(4):850.
Plasma biomarkers of alzheimer's disease: a review of available assays, recent developments, and implications for clinical practice.
Pais MV, Forlenza OV, Diniz BS. J Alzheimers Dis Rep. 2023;7(1):355-380.
Increasing precision of clinical diagnosis of Alzheimer's disease using a combined algorithm incorporating clinical and novel biomarker data.
Sabbagh MN, Lue LF, Fayard D, Shi J. Neurol Ther. 2017;6(suppl 1):83-95.
Donanemab in Early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.
Sims JR, Zimmer JA, Evans CD, et al. JAMA. 2023;330(6):512-527.
Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer’s disease.
Singh D. J Neuroinflammation. 2022;19(1):206.
The central role of tau in Alzheimer's disease: from neurofibrillary tangle maturation to the induction of cell death.
Thal DR, Tomé SO. Brain Res Bull. 2022;190:204-217.
Lecanemab in early Alzheimer’s disease.
van Dyck CH, Swanson CJ, Aisen P, et al. N Engl J Med. 2023;388(1):9-21.
Clinical Practice Guidelines
Lecanemab: appropriate use recommendations.
Cummings J, Apostolova L, Rabinovici GD, et al. J Prev Alzheimers Dis. 2023;10(3):362-377.
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer’s Association Workgroup National Institute on Aging and the Alzheimer’s Association (NIA-AA)
International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease.
Tian M, Civelek AC, Carrio I, et al. Eur J Nucl Med Mol Imaging. 2022;49(3):895-904.
International Nuclear Medicine Consensus on the clinical use of amyloid positron emission tomography in Alzheimer’s disease.
Tian M, Zuo C, Civelek AC, et al. Phenomics. 2023;3(4):375-389.
Patient and Caregiver Resources
AD8 dementia screening interview
Alzheimer’s Association
The Alzheimer’s Questionnaire
Mini-Mental State Exam (MMSE) Alzheimer’s / dementia test: administration, accuracy and scoring
Montreal Cognitive Assessment Test (MoCA) for dementia & Alzheimer’s
Standardized Mini-Cog© Instrument
Improving Alzheimer’s Disease Management
Updates on Patient Diagnosis and Treatment
| Faculty: | Douglas Galasko, MD; Marwan N. Sabbagh, MD, FAAN |
| Release: | 01/31/2024 |
| Expiration: | 01/31/2025 |
